Primary And Acquired Resistance To Egfr Tkis

Although the use of gefitinib and erlotinib in the setting of EGFR-driven cancers has revealed some clinical efficacy, these agents are limited in their beneficial scope. If one examines NSCLC as a representative model for targeting EGFR activity, the overall response rate of patients to gefitinib or erlotinib in published studies is approximately 10% in unselected NSCLC patients in U.S. and European populations. For patients harboring EGFR-activating mutations, the rate of response is between 78% and 100% (69).

Approximately 90% of NSCLC patients with advanced metastatic disease exhibit little or no response to the drugs, a phenomenon referred to as primary or de novo resistance, since it is inherent to the genotypic profile of the patient prior to treatment and does not develop due to selective pressures imposed by the drug. This latter situation is representative of acquired resistance, and will be discussed below.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment